background
substanti
differ
cost
medic
mask
respir
costeffect
analysi
requir
assist
decisionmak
evalu
altern
healthcar
worker
hcw
mask
respir
strategi
studi
aim
compar
costeffect
respir
medic
mask
protect
hcw
beij
china
method
develop
costeffect
analysi
model
utilis
efficaci
resourc
use
data
two
cluster
randomis
clinic
trial
assess
variou
maskrespir
strategi
conduct
hcw
level
beij
hospit
influenza
season
main
outcom
measur
increment
costeffect
ratio
icer
per
clinic
respiratori
ill
cri
case
prevent
use
societ
perspect
includ
intervent
cost
healthcar
cost
cri
hcw
absente
cost
increment
cost
prevent
cri
case
continu
use
respir
compar
medic
mask
rang
us
approx
rmb
oneway
sensit
analysi
indic
cri
attack
rate
intervent
effect
greatest
impact
costeffect
determin
costeffect
maskrespir
strategi
depend
willing
pay
prevent
cri
case
hcw
vari
countri
case
highli
pathogen
pandem
respir
use
hcw
would
like
costeffect
intervent
healthcar
worker
hcw
increas
risk
contract
influenza
respiratori
infect
compar
rest
adult
work
popul
use
respir
mask
reduc
transmiss
infect
within
hospit
decreas
cost
associ
hcw
absente
cost
nosocomi
infect
vulner
patient
maskrespir
avail
also
crucial
context
emerg
respiratori
infect
threat
hcw
effect
pharmaceut
intervent
may
avail
eg
sever
acut
respiratori
syndrom
sar
epidem
middl
east
respiratori
syndrom
mer
outbreak
sinc
medic
mask
refer
surgic
mask
countri
design
protect
wearer
aerosol
transmiss
droplet
nuclei
viral
particl
respir
special
engin
purpos
respir
model
test
proven
least
particl
filter
effici
world
health
organ
us
centr
diseas
control
prevent
cdc
recommend
use
mask
lowrisk
set
respir
highrisk
set
eg
aerosol
gener
procedur
protect
healthcar
worker
hcw
season
influenza
context
influenza
recommend
similar
precaut
advis
season
influenza
cdc
recommend
least
equival
fit
test
respir
hcw
contact
pandem
influenza
patient
even
aerosolgener
procedur
conduct
substanti
differ
cost
respir
mask
may
affect
develop
countri
specif
maskrespir
guidelin
hcw
anoth
potenti
import
consider
fit
test
add
cost
respir
use
may
help
ensur
seal
respir
hcw
face
recent
review
identifi
lack
econom
evalu
use
clinic
efficaci
estim
assess
costeffect
maskrespir
use
healthcar
set
aim
present
studi
compar
costeffect
respir
mask
intervent
hcw
use
data
two
larg
clinic
trial
conduct
beij
hospit
two
previous
publish
cluster
randomis
trial
use
econom
evalu
design
measur
efficaci
respir
medic
mask
protect
hcw
respiratori
infect
beij
hospit
trial
design
unit
randomis
entir
emerg
depart
respiratori
ward
level
hospit
assign
intervent
particip
hcw
work
enrol
ward
ie
nurs
doctor
administr
staff
ward
select
consid
highrisk
set
occup
exposur
respiratori
infect
intervent
period
first
trial
trial
winter
decemb
januari
second
trial
trial
intervent
period
follow
winter
decemb
januari
trial
continu
use
fit
test
nonfit
test
respir
compar
medic
mask
continu
use
refer
wear
respir
medic
mask
entir
shift
deem
uneth
randomis
ward
control
arm
ie
mask
use
conveni
sampl
hcw
hospit
document
prestudi
low
rate
mask
use
recruit
arm
exclud
econom
analysi
due
lack
randomis
trial
two
fit
test
respir
arm
differ
arm
one
arm
employ
continu
respir
use
carri
target
ie
select
respir
use
hcw
whilst
conduct
highrisk
procedur
common
aerosolgener
procedur
barrier
nurs
patient
known
respiratori
ill
arm
compar
continu
use
medic
mask
arm
use
trial
trial
number
hcw
per
arm
continu
medic
mask
continu
fit
test
continu
nonfit
test
arm
respect
trial
number
hcw
per
arm
continu
medic
mask
target
fit
test
continu
fit
test
arm
respect
criterion
clinic
respiratori
ill
cri
trial
present
two
respiratori
symptom
one
respiratori
symptom
one
system
symptom
respiratori
symptom
consid
cough
nasal
congest
rhinorrhoea
sore
throat
sneez
system
symptom
consid
temperatur
perceiv
chill
andor
fever
lethargi
loss
appetit
myalgia
respir
mask
use
trial
sourc
manufactur
china
model
suppli
trial
discontinu
china
follow
season
differ
model
respir
mask
type
suppli
trial
trial
includ
least
one
arm
appli
qualit
fit
test
particip
hcw
begin
trial
period
accord
manufactur
instruct
adopt
societ
perspect
recommend
costeffect
analysi
guidelin
includ
cost
intervent
addit
inpati
outpati
cost
healthcar
system
hcw
cri
case
indirect
product
cost
includ
min
staff
time
lost
fit
test
respir
due
hcw
absente
cri
outofpocket
cost
includ
cost
medic
outpati
visit
healthcar
centresfev
clinic
emerg
ward
cri
potenti
outofpocket
cost
incur
hcw
cri
healthcar
copay
direct
nonmed
cost
eg
transport
cost
exclud
trial
data
collect
item
appli
decis
analyt
model
use
microsoft
excel
construct
separ
econom
evalu
trial
cost
health
outcom
discount
time
horizon
analysi
less
one
year
day
primari
outcom
increment
cost
effect
ratio
icer
per
cri
case
prevent
chosen
cri
hcw
primari
endpoint
trial
cri
case
patient
record
oneway
sensit
analysi
carri
rang
paramet
identifi
substanti
impact
icer
scenario
analysi
examin
season
variat
attack
rate
cri
captur
valu
outsid
observ
year
trial
run
adjust
confound
trial
found
continu
use
nonfit
test
arm
significantli
protect
cri
medic
mask
howev
combin
arm
includ
fit
test
nonfit
test
group
signific
differ
group
found
significantli
protect
posthoc
cluster
confound
adjust
analysi
compar
medic
mask
reason
calcul
icer
result
trial
use
efficaci
estim
arm
howev
explor
impact
fit
test
costeffect
select
either
includedexclud
cost
fit
test
arm
trial
result
cluster
confound
adjust
continu
use
fit
test
arm
significantli
protect
effect
compar
medic
mask
exclud
target
use
fit
test
arm
econom
analysi
signific
differ
result
arm
compar
medic
mask
cri
rate
observ
arm
trial
use
report
preliminari
result
arm
howev
estim
icer
cri
rate
gener
intentiontotreat
cluster
confound
adjust
signific
efficaci
result
trial
inform
intervent
efficaci
number
respir
mask
use
per
shift
shift
durat
obtain
trial
public
data
hcw
resourc
use
due
cri
case
exact
proport
staff
type
arm
number
shift
work
number
day
leav
taken
extract
trial
databas
healthcar
resourc
use
cost
treatment
sourc
beij
pharmaceut
sunshin
procur
platform
estim
use
cost
visit
healthcar
centr
emerg
depart
staff
monthli
salari
cost
xiaoli
wang
beij
cdc
person
commun
juli
estim
salari
cost
compar
approxim
nation
bureau
statist
china
averag
health
social
work
salari
cost
report
us
dollar
chines
renminbi
use
exchang
rate
usd
tabl
trial
separ
respir
mask
cost
per
hcw
arm
calcul
multipli
mean
number
shift
work
day
trial
period
cost
either
two
respir
three
medic
mask
provid
per
hcw
shift
work
trial
hcw
work
averag
shift
trial
shift
trial
trial
durat
typic
shift
eight
hour
durat
fit
test
arm
mean
cost
min
hcw
time
fit
test
includ
take
account
proport
staff
type
doctor
nurs
etc
trial
fit
tester
time
includ
cost
min
administr
staff
member
time
per
hcw
us
rmb
trial
us
rmb
trial
cost
calcul
monthli
salari
estim
differ
trial
hcw
work
slightli
shift
per
month
averag
trial
test
oper
selftaught
includ
train
cost
respir
mask
fit
test
kit
cost
appli
shown
inform
direct
healthcar
resourc
use
hcw
document
cri
trial
collect
survey
complet
person
hcw
symptom
requir
report
ward
head
nurs
survey
complet
provid
data
differ
type
treatment
use
hcw
specif
cri
episod
number
healthcar
centrefev
clinic
visit
emerg
ward
visit
use
calcul
mean
cost
cri
hcw
trial
indirect
cost
term
product
loss
due
hcw
take
leav
cri
episod
estim
use
human
capit
approach
mean
leav
cost
per
hcw
cri
trial
calcul
take
account
proport
staff
type
took
leav
product
cost
per
day
leav
calcul
divid
mean
monthli
incom
averag
number
shift
hcw
day
trial
period
ie
shift
trial
trial
trial
cri
attack
rate
alloc
continu
use
withwithout
fit
test
respect
alloc
medic
mask
use
arm
tabl
trial
cri
attack
rate
alloc
fit
test
respir
compar
alloc
medic
mask
use
arm
tabl
also
compar
cri
attack
rate
target
use
fit
test
arm
trial
exclud
analysi
due
lack
statist
differ
compar
medic
mask
arm
intervent
cost
per
hcw
trial
day
us
rmb
continu
use
nonfit
test
arm
nearli
twofold
higher
continu
use
fit
test
arm
us
beij
pharmaceut
sunshin
procur
platform
antituss
eg
apricot
cough
syrup
ml
bottl
beij
pharmaceut
sunshin
procur
platform
antipyret
eg
paracetamol
tablet
beij
pharmaceut
sunshin
procur
platform
antivir
eg
oseltamivir
tablet
beij
pharmaceut
sunshin
procur
platform
tradit
chines
medicin
eg
ganmao
qingr
granul
bag
beij
pharmaceut
sunshin
procur
platform
healthcar
rmb
us
rmb
medic
mask
arm
tabl
result
trial
similar
intervent
cost
per
hcw
us
arm
us
rmb
per
hcw
medic
mask
use
arm
tabl
mean
cri
cost
per
hcw
case
low
arm
compar
intervent
cost
tabl
commonli
report
treatment
use
cri
trial
trial
trial
tradit
chines
medicin
commonli
ganmo
qingr
granul
us
rmb
breakdown
mean
cri
cost
per
hcw
mean
intervent
cost
per
hcw
respect
trial
intervent
arm
shown
fig
costeffect
estim
describ
focus
around
intentiontotreat
trial
efficaci
result
respir
show
signific
protect
effect
cri
compar
medic
mask
adjust
cluster
confound
shown
bold
tabl
trial
includ
cost
fit
test
icer
continu
respir
use
us
rmb
per
cri
case
prevent
compar
medic
mask
use
trial
icer
us
rmb
continu
fit
test
respir
use
compar
medic
mask
use
differ
trial
primarili
explain
higher
cri
attack
rate
trial
tabl
trial
exclud
cost
fit
test
icer
continu
respir
use
us
rmb
per
cri
case
prevent
compar
medic
mask
use
respons
rel
low
fit
test
failur
observ
trial
oneway
sensit
analysi
indic
cri
attack
rate
intervent
effect
greatest
impact
icer
fig
scenario
assum
attack
rate
greater
approxim
continu
nonfit
test
respir
fit
test
respir
icer
us
rmb
per
cri
case
prevent
see
fig
import
attack
rate
also
shown
overlap
trial
result
continu
fit
test
arm
model
background
cri
attack
rate
medic
mask
arm
see
fig
trial
icer
worsen
substanti
lower
effect
valu
trial
confid
interv
appli
see
tabl
fig
sensit
analysi
also
carri
cost
treatment
includ
healthcar
visit
impact
doubl
halv
cost
respir
see
tabl
fig
potenti
intervent
costsav
estim
assum
sever
ill
treatment
cost
cri
case
us
rmb
extrem
scenario
unlik
except
highli
pathogen
influenza
epidemicpandem
mean
case
requir
substanti
healthcar
treatment
estim
increment
cost
prevent
cri
case
hcw
continu
respir
intervent
compar
medic
mask
rang
us
rmb
set
accept
rang
found
includ
fit
test
respir
intervent
approxim
doubl
cost
intervent
substanti
decreas
costeffect
per
cri
case
prevent
compar
medic
mask
season
low
cri
attack
rate
howev
result
must
interpret
caution
low
respir
fit
test
failur
rate
observ
trial
may
specif
respir
model
use
trial
potenti
polici
option
could
forego
fit
test
respir
known
low
fit
test
failur
rate
use
use
trial
although
decis
requir
care
consider
would
depend
sever
circul
pathogen
increment
approach
consid
addit
cost
benefit
fit
test
may
particularli
import
set
resourc
limit
choic
must
made
fit
test
potenti
lifesav
intervent
present
insuffici
literatur
support
low
failur
rate
seen
trial
would
appli
respir
model
also
found
variat
cri
attack
rate
major
factor
determin
costeffect
respir
see
fig
higher
attack
rate
trial
like
due
activ
influenza
season
observ
influenza
season
incid
sever
cri
case
occur
given
year
vari
accord
transmiss
pathogen
annual
influenza
strain
circul
season
increment
cost
per
cri
case
prevent
continu
use
respir
compar
medic
mask
found
substanti
lower
high
attack
rate
season
fig
import
season
variat
account
evalu
costeffect
influenza
prevent
measur
whilst
result
studi
indic
costeffect
econom
evalu
usual
seen
transfer
set
maskrespir
intervent
hcw
need
evalu
countri
separ
account
intercountri
variat
factor
intervent
accept
healthcar
cost
product
cost
variat
within
countri
also
possibl
henc
result
studi
includ
trial
data
beij
hospit
may
generalis
set
china
china
compar
high
cultur
accept
maskrespir
use
compar
western
countri
furthermor
studi
beij
hcw
regard
suggest
hcw
set
may
continu
attend
work
symptom
influenza
like
ill
may
partial
explain
rel
low
level
absente
hcw
cri
trial
low
mean
healthcar
cost
cri
trial
may
due
rel
modest
influenza
season
low
level
healthcar
seek
staff
exist
econom
studi
masksrespir
suggest
intervent
like
costeffect
high
incom
set
examin
howev
difficult
compar
result
evalu
previou
high
incom
set
studi
often
report
result
easili
compar
format
eg
cost
per
case
prevent
use
clinic
trial
efficaci
data
inform
analys
limit
origin
trial
day
durat
mean
result
may
translat
longer
term
intervent
may
differ
adher
level
limit
analysi
effect
intervent
cri
rate
patient
famili
member
hcw
could
includ
due
absenc
data
exclus
factor
make
result
conserv
hcw
known
transmit
variou
type
nosocomi
infect
patient
literatur
indic
like
substanti
benefit
number
patient
cri
reduc
exampl
benefit
prevent
hcw
infect
transmiss
vaccin
observ
longterm
care
facil
found
associ
decreas
mortal
elderli
resid
differ
mean
direct
healthcar
cost
per
hcw
cri
trial
ie
us
rmb
trial
us
rmb
trial
may
partli
reflect
variat
thorough
sick
followup
data
collect
trial
anoth
potenti
limit
studi
stochast
uncertainti
directli
explor
use
individu
level
data
trial
instead
adopt
decisionmodel
base
approach
use
clinic
trial
data
inform
input
paramet
valu
explor
uncertainti
valu
determinist
sensit
analys
approach
facilit
focu
form
uncertainti
unrel
sampl
potenti
interyear
variat
cri
attack
rate
final
data
qualiti
life
collect
trial
chose
focu
econom
analysi
primari
trial
outcom
cri
limit
abil
compar
valu
money
offer
intervent
econom
evalu
first
econom
analysi
maskrespir
intervent
conduct
middl
incom
set
one
first
make
use
clinic
trial
evid
evalu
provid
valuabl
evid
use
decis
maker
help
assess
cost
benefit
altern
hcw
maskrespir
protect
strategi
determin
costeffect
depend
willing
pay
prevent
cri
case
hcw
vari
countri
easili
transferr
differ
set
extent
decis
maker
like
focu
costeffect
evid
come
hcw
protect
part
depend
serious
infect
prevent
case
highli
pathogen
pandem
respir
use
hcw
would
like
costeffect
intervent
would
like
thank
abrar
chughtai
contribut
studi
work
support
nhmrc
centr
research
excel
integr
system
epidem
respons
iser
grant
number
provid
suppli
respir
medic
mask
origin
investigatordriven
trial
china
data
use
studi
publish
beij
mask
respir
hcw
clinic
trial
obtain
research
led
studi
enquiri
regard
data
direct
dr
holli
seal
hseal
unsweduau
high
low
efficaci
estim
calcul
confid
interv
gener
cluster
confound
adjust
result
trial
respect
b
sever
ill
treatment
cost
cri
case
unlik
except
highli
pathogen
influenza
epidemicpandem
averag
case
requir
substanti
healthcar
treatment
